Whalen Wealth Management Inc. Reduces Position in Insulet Corporation $PODD

Whalen Wealth Management Inc. cut its stake in shares of Insulet Corporation (NASDAQ:PODD) by 56.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,390 shares of the medical instruments supplier’s stock after selling 1,789 shares during the quarter. Whalen Wealth Management Inc.’s holdings in Insulet were worth $437,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PODD. Larson Financial Group LLC grew its holdings in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the first quarter valued at $26,000. SouthState Corp grew its holdings in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. purchased a new stake in shares of Insulet during the second quarter valued at $32,000. Finally, Trust Co. of Toledo NA OH purchased a new stake in shares of Insulet during the second quarter valued at $35,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Stifel Nicolaus started coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price for the company. Royal Bank Of Canada boosted their target price on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. The Goldman Sachs Group decreased their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Finally, Jefferies Financial Group restated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $352.11.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Down 0.4%

Shares of Insulet stock opened at $324.34 on Wednesday. The firm has a 50-day simple moving average of $327.59 and a two-hundred day simple moving average of $306.05. The company has a market cap of $22.83 billion, a P/E ratio of 98.58, a price-to-earnings-growth ratio of 2.72 and a beta of 1.40. Insulet Corporation has a fifty-two week low of $227.03 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.